ADC Therapeutics SA (ADCT)

NYSE: ADCT · Pharmaceutical Preparations · Epalinges, CH · filing with the SEC since 2019

Full chart Alerts Compare

Grade5.3

◀ Past 5.5● Present 4.8▶ Future 6.0

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$81.4M+14.9%

Net income-$143M+9.6%

Earnings per share$-1.12+30.9%

Operating cash flow-$141M-14.0%

Cash$261M+4.2%

Debtn/a

Shareholders’ equity-$186M+8.3%

Shares, diluted127.1M+30.8%

Return on equityn/a

The recordfrom its filings

Filings in 202657

Newest filingNov 10 · S-3

Annual reportMar 10, 2026

Quarterly reportNov 9, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted22

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $84.9MNet income -$81.2MCash from operations -$101Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

22232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form S-3

Shelf registration

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form S-4

Merger or exchange registration

Open the filing on sec.gov

Oct 29, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form S-8

Employee stock plan registration

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

ADC Therapeutics SA is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Epalinges, CH. Product was 90% of fiscal 2025 revenue.

Newest on the record

Shelf registration on Nov 10. Before it, quarterly report on Nov 9.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About ADCT

ADC Therapeutics SA is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Epalinges, CH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $81 million and a loss of $143 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersEpalinges, CH

Business modelProduct business

ExchangeNYSE

Filing since2019

Fiscal year endsDec 31

SEC number (CIK)1771910

Peers on fileSPRY, LQDA, ANAB, KROS

Who runs it

Financial performance

In fiscal 2025 ADC Therapeutics SA’s revenue was $81.36 million, up 14.9% from $70.84 million the year before. It made a net loss of $142.6 million.

Annual report, filed Mar 10, 2026.

Financial statements

The grade

ADC Therapeutics SA grades 5.3 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past5.5

● Present4.8

▶ Future6.0

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton ADCT · research, not advice